Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by PATTRICK, M.
Right arrow Articles by DOHERTY, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PATTRICK, M.
Right arrow Articles by DOHERTY, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

research-article

CHLORMEZANONE IN PRIMARY FIBROMYALGIA SYNDROME: A DOUBLE BLIND PLACEBO CONTROLLED STUDY

M. PATTRICK, A. SWANNELL and M. DOHERTY

Rheumatology Unit City Hospital, Nottingham NG5 2ND

Correspondence to: *Correspondence to M. Pattrick, North Manchester General Hospital, Central Drive, Crumpsall, Manchester M8 6RB

Primary fibromyalgia syndrome (PFS) is a common condition that often proves resistant to health interventions. Chlormezanone combines corrective effects on disturbed sleep with muscle-relaxant properties, and therefore could be of potential benefit in PFS.

Forty-two female patients with PFS (mean age 49, range 24–72 years) were randomly and blindly allocated either chlormezanone 400 mg nocte or placebo. Patients were assessed by single observer at 0, 3 and 6 weeks of treatment; assessments included sleep quality, inactivity and morning stiffness, morning alertness, tender point score, mood change and global opinion (patient and observer). No beneficial therapeutic effect could be attributed to chlormezanone. Although there are problems in assessing severity of a predominantly subjective condition, this essentially negative finding is of interest in respect to the pathogenesis of PFS.

KEY WORDS: Fibromyalgia, Chlormezanone, Sleep disturbance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
J.-C. Roujeau, J. P. Kelly, L. Naldi, B. Rzany, R. S. Stern, T. Anderson, A. Auquier, S. Bastuji-Garin, O. Correia, F. Locati, et al.
Medication Use and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis
N. Engl. J. Med., December 14, 1995; 333(24): 1600 - 1608.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.